Neil Brewis
Chief Executive Officer at F-STAR THERAPEUTICS, INC.
Active connections
| Name | Gender | Age | Linked companies | Collaboration |
|---|---|---|---|---|
| Eliot Forster | M | 58 |
F-star Alpha Ltd.
 F-star Alpha Ltd. BiotechnologyHealth Technology F-star Alpha Ltd. develops novel bispecific antibody products. It focuses on treatment of breast and gastric cancer among a population of HER2-positive patients who do not respond or become resistant to current therapies. The company was founded in October 2013 and is headquartered in Cambridge, the United Kingdom. | 6 years |
| Nessan Bermingham | M | 51 |
F-star Alpha Ltd.
F-star Alpha Ltd. BiotechnologyHealth Technology F-star Alpha Ltd. develops novel bispecific antibody products. It focuses on treatment of breast and gastric cancer among a population of HER2-positive patients who do not respond or become resistant to current therapies. The company was founded in October 2013 and is headquartered in Cambridge, the United Kingdom.
F-star Therapeutics Ltd.
 F-star Therapeutics Ltd. Pharmaceuticals: MajorHealth Technology F-Star Therapeutics Ltd. is a biopharmaceutical company, which engages in the development of immune-oncology drugs for antibody therapies. The company was founded in 2006 and is headquartered in Cambridge, the United Kingdom. | 6 years |
| Patrick Johan Hendrik Krol | M | 60 |
F-star Alpha Ltd.
F-star Alpha Ltd. BiotechnologyHealth Technology F-star Alpha Ltd. develops novel bispecific antibody products. It focuses on treatment of breast and gastric cancer among a population of HER2-positive patients who do not respond or become resistant to current therapies. The company was founded in October 2013 and is headquartered in Cambridge, the United Kingdom.
F-star Therapeutics Ltd.
F-star Therapeutics Ltd. Pharmaceuticals: MajorHealth Technology F-Star Therapeutics Ltd. is a biopharmaceutical company, which engages in the development of immune-oncology drugs for antibody therapies. The company was founded in 2006 and is headquartered in Cambridge, the United Kingdom. | 4 years |
| Phil Thomson | M | - | 13 years | |
| Emma Walmsley | F | 55 | 14 years | |
| Geoff Race | M | 63 |
F-star Therapeutics Ltd.
F-star Therapeutics Ltd. Pharmaceuticals: MajorHealth Technology F-Star Therapeutics Ltd. is a biopharmaceutical company, which engages in the development of immune-oncology drugs for antibody therapies. The company was founded in 2006 and is headquartered in Cambridge, the United Kingdom. | 5 years |
| Lindsey Trickett | F | - | - | |
| Tolga Hassan | M | 53 |
F-star Alpha Ltd.
F-star Alpha Ltd. BiotechnologyHealth Technology F-star Alpha Ltd. develops novel bispecific antibody products. It focuses on treatment of breast and gastric cancer among a population of HER2-positive patients who do not respond or become resistant to current therapies. The company was founded in October 2013 and is headquartered in Cambridge, the United Kingdom. | - |
| Helmut Schühsler | M | 65 |
F-star Alpha Ltd.
F-star Alpha Ltd. BiotechnologyHealth Technology F-star Alpha Ltd. develops novel bispecific antibody products. It focuses on treatment of breast and gastric cancer among a population of HER2-positive patients who do not respond or become resistant to current therapies. The company was founded in October 2013 and is headquartered in Cambridge, the United Kingdom.
F-star Therapeutics Ltd.
F-star Therapeutics Ltd. Pharmaceuticals: MajorHealth Technology F-Star Therapeutics Ltd. is a biopharmaceutical company, which engages in the development of immune-oncology drugs for antibody therapies. The company was founded in 2006 and is headquartered in Cambridge, the United Kingdom. | - |
| Jean-Francois Formela | M | 67 |
F-star Alpha Ltd.
F-star Alpha Ltd. BiotechnologyHealth Technology F-star Alpha Ltd. develops novel bispecific antibody products. It focuses on treatment of breast and gastric cancer among a population of HER2-positive patients who do not respond or become resistant to current therapies. The company was founded in October 2013 and is headquartered in Cambridge, the United Kingdom.
F-star Therapeutics Ltd.
F-star Therapeutics Ltd. Pharmaceuticals: MajorHealth Technology F-Star Therapeutics Ltd. is a biopharmaceutical company, which engages in the development of immune-oncology drugs for antibody therapies. The company was founded in 2006 and is headquartered in Cambridge, the United Kingdom. | - |
| Deborah Harland | M | 64 |
F-star Alpha Ltd.
F-star Alpha Ltd. BiotechnologyHealth Technology F-star Alpha Ltd. develops novel bispecific antibody products. It focuses on treatment of breast and gastric cancer among a population of HER2-positive patients who do not respond or become resistant to current therapies. The company was founded in October 2013 and is headquartered in Cambridge, the United Kingdom.
F-star Therapeutics Ltd.
F-star Therapeutics Ltd. Pharmaceuticals: MajorHealth Technology F-Star Therapeutics Ltd. is a biopharmaceutical company, which engages in the development of immune-oncology drugs for antibody therapies. The company was founded in 2006 and is headquartered in Cambridge, the United Kingdom. | - |
| John Sørensen Haurum | M | 61 |
F-star Alpha Ltd.
F-star Alpha Ltd. BiotechnologyHealth Technology F-star Alpha Ltd. develops novel bispecific antibody products. It focuses on treatment of breast and gastric cancer among a population of HER2-positive patients who do not respond or become resistant to current therapies. The company was founded in October 2013 and is headquartered in Cambridge, the United Kingdom. | - |
| Victoria Whyte | F | - | 15 years | |
| James Sandy | M | - | 2 years | |
| María Cristina de Luna Basagoiti | F | - | 14 years | |
| John Blodgett Edwards | M | - |
F-star Alpha Ltd.
F-star Alpha Ltd. BiotechnologyHealth Technology F-star Alpha Ltd. develops novel bispecific antibody products. It focuses on treatment of breast and gastric cancer among a population of HER2-positive patients who do not respond or become resistant to current therapies. The company was founded in October 2013 and is headquartered in Cambridge, the United Kingdom. | - |
| Frannie DeFranco | F | - | 14 years | |
| Anita Kidgell | F | - | 16 years | |
| Trish Hurley | F | - | - |
Connections Chart
Multi-company connection
Former connections
| Name | Gender | Age | Linked companies | Collaboration |
|---|---|---|---|---|
| Darlene Deptula-Hicks | F | 66 | 3 years | |
| Thomas Mount | M | - | 7 years | |
| Philip Hampton | M | 70 | 4 years | |
| Roy Anderson | M | 76 | 11 years | |
| Vindi Banga | M | 69 | 7 years | |
| Urs Rohner | M | 65 | 9 years | |
| Edward Benz | M | 78 | 4 years | |
| Ian Tomlinson | M | - |
Domantis Ltd.
 Domantis Ltd. Pharmaceuticals: MajorHealth Technology Domantis Ltd. develops domain antibody therapeutics for treating highly unmet diseases. It enables DABS to serve as building blocks for therapeutics simultaneously directed at more than one disease target. The company was founded in December 2000 and is headquartered Middlesex, the United Kingdom. | 6 years |
| Jing Ulrich | F | 56 | - | |
| Pamela Klein | M | 63 | 3 years | |
| Julian Heslop | M | 70 | 13 years | |
| Robert Welna | M | - |
Domantis Ltd.
Domantis Ltd. Pharmaceuticals: MajorHealth Technology Domantis Ltd. develops domain antibody therapeutics for treating highly unmet diseases. It enables DABS to serve as building blocks for therapeutics simultaneously directed at more than one disease target. The company was founded in December 2000 and is headquartered Middlesex, the United Kingdom. | 5 years |
| Stephanie Burns | M | 69 | 9 years | |
| Ravi Rao | M | 55 | 7 years | |
| Anjali Bansal | F | 53 | 6 years | |
| Balbir Kelly Bisla | F | - | 4 years | |
| Christopher Viehbacher | M | 64 | 20 years | |
| Lynn Elsenhans | F | 68 | 10 years | |
| Todd Brady | M | 52 | 3 years | |
| Christopher Gent | M | 75 | 11 years | |
| Robert Carr | M | - | 26 years | |
| David Arkowitz | M | 62 | 3 years | |
| Ben Woolven | M | - |
Domantis Ltd.
Domantis Ltd. Pharmaceuticals: MajorHealth Technology Domantis Ltd. develops domain antibody therapeutics for treating highly unmet diseases. It enables DABS to serve as building blocks for therapeutics simultaneously directed at more than one disease target. The company was founded in December 2000 and is headquartered Middlesex, the United Kingdom. | 19 years |
| Judy Lewent | F | 75 | 10 years | |
| Jean-Pierre Garnier | M | 75 | 8 years | |
| Ian Maurice Gray Prosser | M | 81 | 9 years | |
| Robert Wilson | M | 81 | 11 years | |
| H. Culp | M | 60 | 9 years | |
| James Murdoch | M | 51 | 3 years | |
| Simon Dingemans | M | 61 | 8 years | |
| Crispin Davis | M | 75 | 10 years | |
| Gerardus Johannes Wijers | M | 74 | 3 years | |
| Tom de Swaan | M | 78 | 9 years | |
| Stacey Cartwright | F | 60 | 5 years | |
| Christopher D. Roberts | M | 54 | - | |
| Wladimir Hogenhuis | M | 59 | 6 years | |
| Kim Sablich | F | 55 | 8 years | |
| Jeff McLaughlin | M | - | - | |
| Abid Ansari | M | 46 | 5 years | |
| Martin Andrews | M | 61 | 10 years | |
| Jay Green | M | 52 | 6 years | |
| Cedrik M. Britten | M | 49 | 5 years | |
| Lisa Johnson-Pratt | M | 60 | 6 years | |
| Michele LaRussa | F | 54 | 4 years | |
| Lini Pandite | M | 65 | 14 years | |
| Joe McCann | M | 47 | 4 years | |
| Min Li | M | 62 | 6 years | |
| Amin Khan | M | 61 | 6 years | |
| Jane Hughes | M | 50 | 3 years | |
| Chao Hong Hu | M | 58 | 1 years | |
| Filippo Lanzi | M | - | 9 years | |
| Jing Ji | M | 54 | 4 years | |
| Hu Li | M | 59 | 19 years | |
| Tomoko Maeda-Chubachi | M | - | 3 years | |
| David M. Pernock | M | 69 | 16 years | |
| Paul-Peter Tak | M | 64 | 7 years | |
| Shah Hussain | M | 59 | 9 years | |
| Gregory Perry | M | 63 |
Domantis Ltd.
Domantis Ltd. Pharmaceuticals: MajorHealth Technology Domantis Ltd. develops domain antibody therapeutics for treating highly unmet diseases. It enables DABS to serve as building blocks for therapeutics simultaneously directed at more than one disease target. The company was founded in December 2000 and is headquartered Middlesex, the United Kingdom. | - |
| Michael D. Rogers | M | 68 | 6 years | |
| Ronaldo Hermann Schmitz | M | 85 | 9 years | |
| Adrian Rawcliffe | M | 52 | 17 years | |
| Gary W. Christianson | M | 69 | 2 years | |
| Randy Maddux | M | 62 | 4 years | |
| Simon Harford | M | 64 | 8 years | |
| Dan Troy | M | 64 | 10 years | |
| Mark Berger | M | 69 | 5 years | |
| Stephen F. Stefano | M | 68 | 29 years | |
| Carol Ashe | F | 66 | 13 years | |
| Lorrie Heinemann | F | - | 4 years | |
| Lawson Macartney | M | 66 | 12 years | |
| Bing Li | M | 55 | 4 years | |
| Michael Owen | M | 73 | 9 years | |
| Catherine Sohn | M | 71 | 28 years | |
| Jay C. Strum | M | - | 14 years | |
| Gregg Brandyberry | M | - | 16 years | |
| Vincent O'Neill | M | 55 | 3 years | |
| Manuel Alves Aivado | M | 53 | 6 years | |
| Neil Barnes | M | - | - | |
| Simon Steel | M | - | 8 years | |
| Lon Cardon | M | 58 | 9 years | |
| Thyagi Thyagarajan | M | - | 38 years |
Statistics
| Country | Connections | % of total |
|---|---|---|
| United Kingdom | 97 | 97.00% |
| Austria | 9 | 9.00% |
Age of Connections
Active
Past
Male
Female
Members of the board
Executives
Origin of connections
- Stock Market
- Insiders
- Neil Brewis
- Personal Network
